To improve the efficacy of gene therapy for cancer, we designed four hammerhead ribozyme adenoviruses (R1 to R4) targeting the exposed regions of survivin mRNA. In addition to the in vitro characterization, which included a determination of the sequence specificity of cleavage by primer extension, assays for cell proliferation and for in vivo tumor growth were used to score for ribozyme efficiency. The resulting suppression of survivin expression induced mitotic catastrophe and cell death via the caspase-3-dependent pathway. Importantly, administration of the ribozyme adenoviruses inhibited tumor growth in a hepatocellular carcinoma xenograft mouse model. Co-expression of R1, R3 and R4 ribozymes synergistically suppressed survivin and, as this combination targets all major forms of the survivin transcripts, produced the most potent anti-cancer effects. The adenoviruses carrying the multiple hammerhead ribozymes described in this report offered a robust gene therapy strategy against cancer.
Defects in apoptosis are a key hallmark of the malignant cells resulting from such factors as the activation of antiapoptotic genes and the repression of pro-apoptotic genes [1] . A well-known anti-apoptotic factor is survivin [2] , which is overexpressed in all types of cancers but is undetectable in normal adult cells. Survivin participates in a variety of cellular processes such as cell division, angiogenesis, apoptosis etc [3] . Survivin negatively regulates apoptosis by interfering with caspase-9-processing [4] . Despite our early findings that it binds to Smac/DIABLO released from mitochondria [5] , how survivin directs crossroad traffic between cell division and apoptosis remains elusive.
Besides serving as a biomarker for cancer diagnosis and prognosis [6, 7] , survivin has been selected as a target for cancer intervention [3] . Forced expression of CDK1-nonphosphorylatable survivin T34A mutant has displayed dominant-negative effects and induces dramatic cell death [8, 9] . Down-regulation of survivin expression by antisense oligonucleotide has exhibited a promising outcome in xenograft models and phase I clinical trials [10, 11] . Other down-regulation approaches involving RNA interference (RNAi) also have produced therapeutic effects in xenograft models [12−14] . However, there has been a long debate as to the specificity and durability of antisense oligonucleotide and RNAi approaches in clinical therapy.
Ribozyme is a powerful new therapeutic tool used to diminish RNA molecules in cells [15] . The hammerhead ribozyme is the smallest and best characterized. It consists of three parts: an invariant catalytic domain with 13 conserved nucleotides in a stem-loop structure and two arms located on each side of the catalytic domain stretched complementary to the target RNA. Hammerhead ribozymes cleave after NUH (where N can be any nucleotide, and H can be any nucleotide except G) sequences of target mRNA to suppress the target protein expression [16] . The substrate specificity of the ribozyme is determined by the paired regions flanking the cleavage site. Binding of ribozymes to its target mRNA is significantly more stringent than short interfering RNA approaches, which often produce off-target effects [17, 18] .
We have used the expression cassette in pGVaL to ensure a high level of expression of the stable ribozyme RNAs for better physical contact with substrate RNA [19] . The substrate RNA has been systematically assessed in vitro, in cell cultures and in mouse tumor xenograft model systems with the human hepatocellular carcinoma as the targeted tumor type.
Materials and Methods

Anti-survivin ribozyme expression plasmid vectors
The coding region (the A of ATG: 1 to A of TGA: 426) of the human survivin mRNA sequence (GenBank accession No. BC008718) was analyzed for exposed regions (loops) using the MFOLD program (http://mfold.bioinfo.rpi.edu/ cgi-bin/rna-form1.cgi). The ribozyme sequences targeting H of the NUH triplet in each of four loops were designated R1 to R4 and +61, +83, +232 and +358, respectively (Fig. 1) . Each pair of the oligonucleotides ( Table 1) were Fig. 1 The hammerhead ribozymes against the survivin mRNA (A) The secondary structure of the survivin mRNA predicted by MFOLD program (http://mfold.bioinfo.rpi.edu/cgi-bin/rna-form1.cgi). The four loop regions chosen for ribozyme (R1 to R4) cleavage are indicated by the circles. (B) The survivin mRNA sequences and the nucleotide sequence expected to be cleaved by each ribozyme are marked 61, 83, 232 and 358, respectively. (C) The survivin mRNA substrate, the ribozymes (R1 to R4), and the pairing and cleaved sites. SPE1 to 3 indicate the primers used for primer extension analysis. The primers SurL and SurR for RT-PCR cloning of the open reading frame of human survivin mRNA are boxed.
Table 1 Oligonucleotides for ribozymes
The underlined are protruding sequence of SalI and PstI sites, respectively. B, bottom strand; U, upper strand.
Ribozymes Sequences R1 (+61)  R1U 5′-TCGACCTTGAATGCTGATGAGTCCGTGCGGACGAAAGAGATGCATGCA-3′  R1B 5′-TGCATCTCTTTCGTCCTCACGGACTCATCAGCATTCAAGG-3′   R2(+83)  R2U 5′-TCGACAGCCCTCCCTGATGAGTCCGTGAGGACGAAAGAAGGGCATGCA-3′  R2B 5′-TGCCCTTCTTTCGTCCTCACGGACTCATCAGGGAGGGCTG-3′   R3(+232)  R3U 5′-TCGACATGCTTTTCTGATGAGTCCGTGAGGACGAAATGTTCCTATGCA-3′  R3B 5′-TAGGAACATTTCGTCCTCACGGACTCATCAGAAAAGCATG-3′ R4(+358) R4U 5′-TCGACTTTCTTCTCTGATGAGTCCGTGAGGACGAAATTGTTGGATGCA-3′ R4B 5′-TCCAACAATTTCGTCCTCACGGACTCATCAGAGAAGAAAG-3′
phosphorylated, annealed and cloned at SalI and PstI sites of pGVaL plasmid vector [19] [ Fig. 2(A) ]. The constructs were designated pGVaL-R1 to R4.
Survivin expression plasmid vector
The survivin coding region (the A of ATG: 1 to A of TGA: 426) was amplified by plaque-forming unit-polymerase chain reaction from the cDNA from SMMC-7721 liver cancer cells with the primers SurL 5′-CCGCTCGAGATG-GGTGCCCCGACG-3′ and SurR 5′-GAAGATCTATCCA-TGGCAGCCAGCT-3′ (BglII and XhoI recognition sequences are underlined, respectively). This was followed by cloning in the downstream phase of the three hemagglutinin (HA) tag sequences of pcDNA-HA vector to form HA-survivin (HAS). The HindIII (blunt) and XbaI luciferase fragment of pGL-3-basic (Promega, Madison, USA) was cloned at the BglII (blunt) and XbaI sites of HAS to generate the plasmid HA-survivin-luciferase (HASL) [ Fig. 2(C) ].
Non-replicative adenoviral-ribozyme vectors
The BamHI/NheI (blunt) fragment of pGVaL and pGVaL-R1 to R4, was placed at BglII/HindIII (blunt) sites of pDC vector using the AdMax™ system (Microbix, Calgary, Canada) to create pDC-GVaL and pDC-R1 to R4, respectively [ Fig. 2(B For the in vitro ribozyme cleavage reaction of HASL RNAs, equal molar amounts (1 mmol) of ribozyme and the HASL RNAs were heat denatured in 10 µl of 50 mM Tris (pH 7.5)/1 mM EDTA, quickly cooled and followed by the addition of MgCl 2 for a final concentration of 10 mM to initiate the cleavage reaction at 37 ºC for 60 min. The cleavage products were NH 4 Ac/ethanol precipitated. They were analyzed for cleavage specificity by primer analysis and for cleavage efficacy by determining the relative luciferase activity and protein amount (Western blot analysis with the HA antibody) of the in vitro translated products. The non-virus control (mock) was made from the cleavage reaction with the in vitro transcribed RNAs from pGVaL.
Two-thirds of both mock and cleaved transcripts were subjected to primer extension analysis with the 5′-end [ 32 P]-labeled DNA primer by T4 polynucleotide kinase [SPE1 for R1 and R2, SPE2 for R3 and SPE3 for R4, as shown in Fig. 1(C) ]. The sequence ladders were made with the same primer, and the HASL template was created by T7 DNA polymerase-based manual-sequencing (Amersham, Buckinghamshire, UK). The remaining one-third of the in vitro cleavage products were in vitro translated (Rabbit Reticulocyte Lysate System; Promega), one-fifth of which were measured for luciferase activity (Promega) in a LB 9506 Lumat luminometer (EG&G, Gaithersburg, USA) and plotted. The cleavage reaction by all four ribozymes was also included in this analysis. The remaining four-fifths of the products were analyzed with anti-HA antibody (Santa Cruz Biotechnology, Santa Cruz, USA) and visualized by SuperSignal West Pico Chemiluminescent Substrate (Pierce, Rockford, USA). The relative densitometric reading of the cleaved over that of the mock (as 100%) was calculated.
Evaluation of the anti-survivin adeno/ribozyme effect in hepatocellular cells SMMC-7721 liver cancer cell line (Cell Bank No. TCHu68; China), and PLC hepatocarcinoma cells (ATCC No. CRL-8024) were cultured at 37 ºC with 5% CO 2 in Dulbecco's modified Eagle's medium (DMEM; Invitrogen, Carlsbad, USA) supplemented with 10% fetal bovine serum (PAA, Pasching, Austria) or 10% newborn bovine serum (Sijiqing, Hangzhou, China). The log-phase cells were continuously infected for 72 h by each virus followed by a 3-[4,5- The semi-quantitative RT-PCR analyses were carried out for survivin, β-actin and ribozymes, respectively, with the primer pairs ( Table 2 ). The expression level of the survivin mRNA was presented as a ratio (the survivin over β-actin densitometric quantification) of the infected cells over the mock control.
Western blot analyses of survivin (anti-survivin antibody; Santa Cruz Biotechnology) and proliferating cell nuclear antigen (PCNA) (anti-PCNA antibody; Santa Cruz Biotechnology) were performed on a 15% SDS-polyacrylamide gel. Western blot analysis of poly(ADP-ribose) polymerase (PARP, 85 kDa; Promega)/PCNA was carried out on a 7.5% SDS-polyacrylamide gel. The relative abundance of the survivin or PARP protein was presented in the density ratio of that over PCNA of the viral-infected cells over that (arbitrarily as 100%) of the non-infected cells.
Immunofluorescence microscopy SMMC-7721 cells were infected with the control (GVaL) and survivin ribozymes (R3 or R134), respectively, followed by fixation in 4% formaldehyde 24 h after infection. Coverslips were then permeabilized with 0.2% Triton X-100 and blocked with PBS containing 0.05% Tween-20 with 1% bovine serum albumin (Sigma, St. Louis, USA). Cells were incubated with primary antibodies (tubulin mouse antibody DM1A, 1:5000 dilution; human anti-centromere antibody ACA, 1:2000 dilution) in a humidified chamber for 1 h and then washed three times in PBS containing 0.05% Tween-20. Texas red-conjugated goat antihuman IgG+IgM and fluorescein-isothiocyanateconjugated rabbit antimouse IgG (Jackson ImmunoResearch, West Grove, USA) were used as the secondary antibodies for visualization of appropriate antigens. DNA was stained with TOTO-3 dye (Invitrogen). Slides were examined with a Leica SP5 confocal microscope (Leica, Heerbrugg, Switzerland) and images were presented with Photoshop.
Inhibitory effect of the anti-survivin adeno/ribozyme on tumor xenograft model
The log-phase SMMC-7721 cells were infected with the virus at multiplicity of infection (MOI) of 10 or 25 for 24 h at 37 ºC before being injected subcutaneously into both flanks (3×10 6 cells/flank) of each mouse (BALB/c, nu/nu). Each group consists of three mice; the left flank of each mouse was injected with SMMC-7721 cells or adeno/GVaL (non-ribozyme viral control) while the right flank was injected with the cells infected with each adeno/ribozyme virus under study. Tumor growth was monitored and measured until the experiment terminated at week 4, when the tumor mass was measured. The weight ratio of the tumor over the mock was determined for each mouse. All animal experiments were approved by the Institutional Review Board and the Animal Research Committee.
The tumor was fixed, sectioned, hematoxylin and eosin (H&E) stained or immunostained for the expression of survivin (1:10 dilution of anti-survivin antibody; FL-142, Santa Cruz Biotechnology) and ki67 protein (1:10 dilution of anti-Ki67 antibody; Novocastra, Newcastle, UK), and visualized by the EnVision System (Dako, Carpinteria, USA).
Results
Design of the anti-survivin hammerhead ribozymes
Four hammerhead ribozymes were designed to cleave respectively at nucleotide +61 (R1), +83 (R2), +232 (R3), and +358 (R4) of the predicted open frames of survivin mRNA (Fig. 1) . The genes were then embedded in the adenoviral Va I RNA of the pGVaL vector [19] [ Fig. 2  (A) ]. By placing the ribozyme genes at the center of a loop formed from an inverted repeat sequence that was artificially introduced into the Val I gene [19] [pGVaL-Rx in Fig. 2(A) ], the ribozyme sequences were expected to protrude from the Va I RNA region. The BamHI and NheI fragment of each pGVaL-R was cloned into the adenoviral vector (Microbix pDC-316 based) to facilitate analysis of both the cellular level and the entire animal and that will ultimately be used to treat cancer in clinical trials [ Fig. 2  (B) ]. The HA-tagged survivin-luciferase fusion gene was put into a pcDNA 3.1-based vector to create HASL [ Fig. 
2(C)]
, so that evaluation of the ribozyme mediated cleavage in vitro of survivin RNA could be readily carried out by primer extension (for both cleaving specificity and efficacy) and luciferase activity (for cleaving efficacy).
Evaluation of survivin mRNA's ribozyme-cleavage specificity and efficacy Except for R3, which failed to target ∆Ex3, all the remaining ribozymes were expected to cleave all the three major forms of survivin mRNAs [20, 21] [ Fig. 3(A) ]. Equal amounts of both ribozymes and the survivin RNAs made by in vitro transcription were incubated in the presence of Mg 2+ for the cleavage reaction. Primer extension analysis of the resulted survivin RNAs showed that each ribozyme cleaved the survivin RNA at the predicted sites [arrowed in Fig. 3(B) ]. Judged from its band density relative to its expected size, R2 appeared to be least efficient ribozyme. The in vitro translated products of the RNA remaining from the cleavage reaction were, respectively, assayed for luciferase activity [ Fig. 3(C) ] and for the size of the HA-associated protein band in Western blot analysis [ Fig. 3(D) ] to semi-quantitatively determine the efficacy of the ribozyme cleavage. The luciferase activity from the mock (100%) was reduced to 62.7% in R1, 70.0% in R2, 40.4% in R3, 57.0% in R4, and 28.7% in a combination of the four ribozyme experiments [ Fig. 3  (C) ] and the HA-associated band density to 48.8% in R1, 124.4% in R2, 28.7% in R3, 61.0% in R4 and 16.5% in a combination of the four ribozyme experiments [ Fig. 3  (D) ]. As the in vitro analyses indicated, R3 was the most effective, followed by R1, R4 and R2. There was an additive effect in cleavage by all the four ribozymes in combination [ Fig. 3(C,D) ]. In view of the protein-free RNA in vitro analyses [ Fig. 3 ], the exposed region of the substrate RNA by the MFOLD program was indeed informative for the rational design of the hammerhead ribozyme.
Ribozyme-mediated cleavage of survivin mRNAinduced apoptosis and mitotic catastrophe in cells SMMC-7721 hepatocellular carcinoma cells were challenged with the non-replicative adenoviral particles carrying a single ribozyme gene (R1 to R4), three ribozymes (R1, R3 and R4) in tandem (R134) or no ribozyme control (GVaL) for 72 h. The loss of cell viability then was assayed by MTT assay [ Fig. 4(A) ], by a semiquantitative PCR analysis for repression of survivin expression [ Fig. 4(B) ] and by Western blot analysis [ Fig.  4(C) ]. Western blot analysis was also used to assess the apoptotic index for the level of PARP protein [ Fig. 4(D) ].
Consistent with the in vitro observations (Fig. 3) , R2 was the least effective ribozyme; infection at MOI of 50 reduced the MMT reading by no more than 20%. R134 was more effective than the most potent single ribozyme, R3; infection at MOI of 12.5 reduced the MTT reading by 23.2% versus 38.6% and at MOI of 25 by 15.2% versus 27.8% [ Fig. 4(A) ]. The levels of ribozyme and β-actin RNAs were comparable, but the survivin mRNA level varied with the ribozyme viruses: GVaL, 91.4% of that of the SMMC-7721 cells; R1, 36.1%; R2, 108.3%; R3, 33.8%; R4, 60.5%; and R134, 22.0% [ Fig. 4(B) ]. These results reflected the relative potency of the ribozyme against survivin mRNA, which was also confirmed by Western blot analysis of survivin protein [ Fig. 4(C) ]. PARP protein (85 kDa) was a specific cleaved product of PARP-1 by caspase-3 in the cell undergoing apoptosis [22] Fig.  4(D) ]. We also performed the same set of analyses on another hepatocellular cell line PLC (ATCC No. CRL-8024) and yielded comparable results (Fig. 5) .
An immunofluorescence study showed that when survivin was depleted of R3 and R134, respectively, SMMC-7721 cells exhibited aberrant chromosome segregation [ Fig. 4(E), d', d"] , a phenotype associated with mitotic catastrophe. Multipolar spindles were typical phenotypes seen in 83%±7% of the infected cells where mitotic chromosomes failed to align at the equator and enter into anaphase [ Fig. 4(E) , c', c"], compared to 5%±3% in GVaL-infected control (n=4). The microtubule integrity and centromere labeling by anti-centromere antibody ACA remained unaltered, confirming the specificity of the ribozyme treatment [ Fig. 4(E) , a', a"].
Adenoviral-ribozymes prevented and suppressed growth of the hepatocellular tumor xenografts in mice
SMMC-7721 cells were infected with viruses at MOI of 25 for 24 h prior to injection into mice. The right flanks of nude mice were injected with SMMC-7721 cells that had been pre-infected with the ribozyme viruses, while the left flank received cells with either no virus (mock) or the empty vector-virus (GVaL) pre-infection [ Fig. 6(A) ]. While no difference in growth profile and tumor mass was observed in the mock-infected SMMC-7721 cells [ Fig.  6(B,D) ], all the ribozyme viruses, except for R2, prevented tumor growth. The tumors from the cells pretreated with R2, the least effective ribozyme, grew significantly more slowly than those pretreated with the mock, and at day 35 when the experiment was ended, had a smaller mass by a ratio of 0.64:1 [ Fig. 6(C,D) ]. Again neither R3 nor R134 at MOI of 10 led to tumor growth; the cells that received the R4 virus grew more slowly than the GVaLinfected cells [ Fig. 6(E−G) ]. Consistent with the reduced tumor growth, expressions of both survivin [ Fig. 6(I) ] and ki67 proteins (a marker for cell proliferation) [ Fig. 6 (J)] were significantly repressed in tumors derived from the cells pre-infected with either R2 at MOI of 25 or R4 at MOI of 10. The growth profile of the GVaL-infected SMMC-7721 cells might have reflected the potential to support tumor expansion that varied with individual animals. The observation that tumor mass in R134 (100%) by the GVaL infection was 2-fold bigger than that in R3 (31%) experiments [ Fig. 6(K,L) ] favored the conclusion from the previous analyses that three ribozymes acting together in R134 would have a greater anti-cancer effect than any single ribozyme (Figs. 3 and 4) .
To mimic the clinical practice of cancer gene therapy, R3 or R134 viruses were injected in a regime of 3×10 than the control viruses [ Fig. 7(E,F) ].
Discussion
The survivin gene has been regarded as a rational target for cancer treatment using new molecular antagonists, cancer vaccines and gene therapeutic agents [3] . Smallmolecule antagonists against survivin, including tetra-Omethyl nordihydroguaiaretic acid to repress Sp1 dependent survivin gene expression and 17-allyl-amino-geldanamycin or shepherdin to disrupt survivin/Hsp90 interaction [23] [24] [25] [26] , have entered phase I and II clinical trials. The use of hammerhead ribozymes seems more advantageous than both RNAi, because of its target specificity, and antisense, because of its deliverability by conventional gene therapeutic vectors, including the adenoviral vector used in this report.
The sequence targeted by the R1 in this report is identical to CUA110, the ribozyme described by Pennati et al that was also placed directly within an adenoviral Va I RNA gene in a retroviral vector [25] . However, all characterizations, including cell viability, apoptosis and in vivo tumor growth, have been performed in stable transformed tumor cell lines. Choi et al constructed a hammerhead ribozyme against the same sequence motif as R3 in this work, where the ribozyme RNA was expressed on its own in an adenoviral system [14] . Both in vitro and in cell results demonstrate its ability to cleave survivin RNA as expected and to induce apoptosis; however, the ability of in vivo to inhibit tumor growth has not been demonstrated.
Here, we show both the specificity and efficacy of each of the four hammerhead ribozymes to cleave the survivin RNA in vitro (Fig. 3) , in cell (Figs. 4,5) , and in vivo (Figs. 6 and 7) . A combination of three ribozymes (R1, R3 and R4) synergistically suppress survivin expression [19] , which is likely attributable to the fact that there are three alternately processed survivin transcripts, designated as survivin (full length), survivin-∆Ex3 (lacking exon 3) and survivin-2B (retaining part of intron 2 as a cryptic exon). All forms of survivin RNAs are required for fullblown apoptosis and aberrant mitosis [20] . A high level of survivin-∆Ex3 reportedly correlates with a poorer prognosis in acute myeloid leukemia and cannot be cleaved by R3 [21] , the most potent single ribozyme. Therefore, using R134 virus, which combines three effective ribozymes, should be advantageous, as it has a higher efficacy at cleaving all the spliced forms of survivin RNA.
In addition to the demonstration of the robust therapeutic potential of hammerhead ribozyme-mediated depletion of survivin expression, this report has detailed a strategy to develop an effective hammerhead ribozyme that aims to repress the expression of a given gene, has a rational design that provides both specificity and efficacy in vitro, in cell culture and in animal, and includes vectors that will address most, if not all, major technical concerns.
